scholarly journals e-Health in Cardiovascular Medicine

2019 ◽  
Vol 7 (6) ◽  
pp. 72
Author(s):  
Julie Redfern ◽  
Lis Neubeck
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cause Of Death ◽  
Disease Burden ◽  
Cardiovascular Medicine ◽  
Artery Disease

Cardiovascular disease (CVD), including coronary artery disease (CHD) and stroke, is the leading cause of death and disease burden globally [...]

scholarly journals The Comparison Between Management Versus Percutaneous Coronary Intervention (PCI) Patients With Coronary Artery Disease (CAD)

2021 ◽  
Vol 03 (06) ◽  
pp. 189-194
Author(s):  
Yuldashev Soatboy Jiyanboyevich ◽  
◽  
Dr. Imran Aslam ◽  
Arslonova Rayxon Rajabboevna ◽  
◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cause Of Death ◽  
Coronary Intervention ◽  
The United States ◽  
Myocardial Infraction ◽  
The Usa ◽  
Artery Disease ◽  
The One

This study is based on the comparison between management versus PCI in patients with CAD. The prevalence of the major forms of cardiovascular disease (CVDs), mostly coronary artery disease (CAD), has changed dramatically in recent years. Cardiovascular disorders are now the one of the major cause of death and disability in the world.1 In 2015, 17.7 million individuals died from cardiovascular disease (CVD), which is around 31% of all deaths worldwide; 7.4 million pass away from coronary artery disease (CAD), and 6.7 million expired from stroke. 2 CAD is also the major cause of death, count for 13.2% of all deaths globally.3 It is responsible for one-quarter of all deaths in the United States of America (USA). About 75 percent of people with CAD in European countries are between the ages of 27 and 34.4 CAD was accountable for 16% of all man deaths and 10% of all female deaths in the England.5 Sudden death and CAD have a close connection. According to post-mortem reports and death certificates, 62-85 percent of patients who expired outside of the clinic have a past of CAD.6 As per informations from the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2014, myocardial infraction affects 3.0% of the mature people in the USA (3.3 percent of males and 2.3 percent of females). An MI occurs every 40 seconds or so in the USA. In the USA, the mean age at 1st MI is 65.6 years for guys and 72.0 years for ladies.7 In this study the management and PCI are compared in patients with CVD.

Optimal medical therapy for coronary artery disease

2021 ◽  
pp. 103-114
Author(s):  
David R. Holmes ◽  
Valentin Fuster
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Peripheral Arterial Disease ◽  
Cause Of Death ◽  
Disease Process ◽  
Arterial Disease ◽  
Developed Economies ◽  
Artery Disease ◽  
Peripheral Arterial

Cardiovascular disease remains the leading cause of death in the United States and the developed world and is becoming increasingly more prevalent globally. Indeed, in less developed nations, cardiovascular disease is now a relatively greater burden than in more developed economies. It is currently the number one cause of death worldwide, as a result of two phenomena, namely increased life expectancy due to successful treatment/prevention of infectious disease as well as increased exposure to known risk factors such as tobacco use, obesity, and a sedentary lifestyle. Cardiovascular disease is typically the result of atherosclerosis which can present as coronary heart disease, cerebrovascular disease, peripheral arterial disease, or aortic atherosclerosis. Given the generalized disease process, many individuals develop and present with more than one clinical manifestation. This has important implications for screening, for example, in patients presenting with clinically evident peripheral arterial disease, consideration should be given for screening to detect the presence of asymptomatic coronary artery disease.

scholarly journals Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease

2021 ◽  
Author(s):  
Rutao Wang ◽  
Scot Garg ◽  
Chao Gao ◽  
Hideyuki Kawashima ◽  
Masafumi Ono ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Coronary Revascularization ◽  
Long Term Outcomes ◽  
Vital Status ◽  
Increased Risk ◽  
Artery Disease ◽  
The Impact

Abstract Aims To investigate the impact of established cardiovascular disease (CVD) on 10-year all-cause death following coronary revascularization in patients with complex coronary artery disease (CAD). Methods The SYNTAXES study assessed vital status out to 10 years of patients with complex CAD enrolled in the SYNTAX trial. The relative efficacy of PCI versus CABG in terms of 10-year all-cause death was assessed according to co-existing CVD. Results Established CVD status was recorded in 1771 (98.3%) patients, of whom 827 (46.7%) had established CVD. Compared to those without CVD, patients with CVD had a significantly higher risk of 10-year all-cause death (31.4% vs. 21.7%; adjusted HR: 1.40; 95% CI 1.08–1.80, p = 0.010). In patients with CVD, PCI had a non-significant numerically higher risk of 10-year all-cause death compared with CABG (35.9% vs. 27.2%; adjusted HR: 1.14; 95% CI 0.83–1.58, p = 0.412). The relative treatment effects of PCI versus CABG on 10-year all-cause death in patients with complex CAD were similar irrespective of the presence of CVD (p-interaction = 0.986). Only those patients with CVD in ≥ 2 territories had a higher risk of 10-year all-cause death (adjusted HR: 2.99, 95% CI 2.11–4.23, p < 0.001) compared to those without CVD. Conclusions The presence of CVD involving more than one territory was associated with a significantly increased risk of 10-year all-cause death, which was non-significantly higher in complex CAD patients treated with PCI compared with CABG. Acceptable long-term outcomes were observed, suggesting that patients with established CVD should not be precluded from undergoing invasive angiography or revascularization. Trial registration SYNTAX: ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050. Graphic abstract

scholarly journals Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden

2013 ◽  
Vol 61 (9) ◽  
pp. 957-970 ◽  
Author(s):  
Kenneth Chan ◽  
Riyaz S. Patel ◽  
Paul Newcombe ◽  
Christopher P. Nelson ◽  
Atif Qasim ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Disease Burden ◽  
Chromosome 9P21 ◽  
Artery Disease ◽  
9P21 Locus

Distal-Vessel FFR-CT To Evaluate Cumulative Coronary Artery Disease Burden

2021 ◽  
Vol 15 (4) ◽  
pp. S23
Author(s):  
M. Chen ◽  
S. Almeida ◽  
K. Shaikh ◽  
C. Shekar ◽  
D. Dey ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Disease Burden ◽  
Artery Disease ◽  
Distal Vessel

CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment

2021 ◽  
Vol 18 ◽  
Author(s):  
Elifcan Gezer ◽  
Mehtap Cevik ◽  
Cansu Selcan Akdeniz ◽  
Ismail Polat Canbolat ◽  
Selen Yurdakul ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Statin Therapy ◽  
Plasma Lipid ◽  
Blood Cholesterol ◽  
Study Group ◽  
Genotype Distribution ◽  
Obese Patients ◽  
Artery Disease

Objective: Coronary artery disease (CAD) is the one of the leading cause of morbidity and mortality worldwide and statins are frequently prescribed in the treatment of CAD to help lower blood cholesterol levels. Since the main enzyme involved in the metabolism of statins is CYP3A4, we aimed to investigate the effect of CYP3A4 * 1B genotypes on plasma lipid profile in Turkish cardiovascular disease subject with and without obesity taking statin. Materials and Methods: The study group consisted of 85 cardiovascular disease patients who were prescribed statins and had routine biochemical analysis data. Polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) assay were performed for genotyping of CYP3A4 *1B (rs2740574) polymorphism. Results: Genotype distribution of CYP3A4 *1B polymorphism was found for homozygous wild (AA) and homozygous polymorphic (GG) genotypes as 94.1% and 5.9% respectively. We did not detect patients with heterozygous genotype in our study group. We found that the mean LDL-c, TG and TC levels were higher in patients with CYP3A4 *1B GG compared to AA genotype. The frequency of CYP3A4 *1B GG genotype frequency (9.5%) was detected higher in the obese patients compared to the non-obese patients (7.7%) (χ2=0.037, p=0.85). Conclusions: Our results demonstrate that CYP3A4 *1B homozygous polymorphic genotype distribution tend to be higher in obese patients compared to non- obese patients with cardiovascular disease which may point *1B allele to have a slight effect on serum lipids during statin therapy. Additional studies with higher samples are needed for evaluating the role of CYP3A4 *1B on lipids in patients under statin therapy.

scholarly journals Epicardial Adipose Tissue as a Source of Nuclear Factor-κB and c-Jun N-Terminal Kinase Mediated Inflammation in Patients with Coronary Artery Disease

2009 ◽  
Vol 94 (1) ◽  
pp. 261-267 ◽  
Author(s):  
A. R. Baker ◽  
A. L. Harte ◽  
N. Howell ◽  
D. C. Pritlove ◽  
A. M. Ranasinghe ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Adipose Tissue ◽  
Coronary Artery ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Toll Like Receptor ◽  
Inflammatory Profile ◽  
Artery Disease ◽  
And Control

Abstract Context: Visceral adipose tissue (AT) is known to confer a significantly higher risk of type 2 diabetes and cardiovascular disease. Epicardial AT has been shown to be related to cardiovascular disease and myocardial function through unidentified mechanisms. Epicardial AT expresses an inflammatory profile of proteins; however, the mechanisms responsible are yet to be elucidated. Objectives: The objectives of the study were to: 1) examine key mediators of the nuclear factor-κB (NFκB) and c-Jun N-terminal kinase (JNK) pathways in paired epicardial and gluteofemoral (thigh) AT from coronary artery disease (CAD) and control patients and 2) investigate circulating endotoxin levels in CAD and control subjects. Design: Serums and AT biopsies (epicardial and thigh) were obtained from CAD (n = 16) and non-CAD (n = 18) patients. Inflammation was assessed in tissue and serum samples through Western blot, real-time PCR, ELISAs, and activity studies. Results: Western blotting showed epicardial AT had significantly higher NFκB, inhibitory-κB kinase (IKK)-γ, IKKβ, and JNK-1 and -2 compared with thigh AT. Epicardial mRNA data showed strong correlations between CD-68 and toll-like receptor-2, toll-like receptor-4, and TNF-α. Circulating endotoxin was elevated in patients with CAD compared with matched controls [CAD: 6.80 ± 0.28 endotoxin unit(EU)/ml vs. controls: 5.52 ± 0.57 EU/ml; P&lt;0.05]. Conclusion: Epicardial AT from patients with CAD shows increased NFκB, IKKβ, and JNK expression compared with both CAD thigh AT and non-CAD epicardial AT, suggesting a depot-specific as well as a disease-linked response to inflammation. These studies implicate both NFκB and JNK pathways in the inflammatory profile of epicardial AT and highlight the role of the macrophage in the inflammation within this tissue.

Sign in / Sign up

Export Citation Format

Share Document